Tesla Wipes Out New Content Marketing Unit, Fired All Team Members 
Starbucks Drops Limited-Edition Motto Frappuccino in Japan Stores 
Why is the London Stock Exchange losing out to the US 
US Supreme Court Signals Support for Starbucks in Landmark Labor Law Case 
The language of insolvency: why getting it wrong can harm struggling firms 
Visa's Q2 Earnings Surpass Expectations, Fueled by Consumer Spending 
Crypto.com's Launch in South Korea Stalled by AML Regulatory Concerns, Postponement Announced 
ADM’s Suspended CFO to Resign After Accounting Probe 
Philippines SEC Directs Google, Apple to Delist Binance App Over Investor Security Concerns 
Tesla Reveals Plans to Release New EVs Earlier Than Scheduled, to Introduce Cheaper Models 
LG Energy Solution to Combat Infringement By Launching Licensing Business for Battery Patents 
Coca-Cola, Microsoft Forge $1.1B Alliance for Cloud and AI Innovation 
China Secures Banned Nvidia Chips Amid US Export Restrictions, Tenders Reveal 
Tesla to Lay Off 2,700 in Austin, Over 3,300 in California Under Restructuring Scheme 
Amazon to Introduce Air Delivery Service in Arizona via Drone 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27th, 2017 at 2:15 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available on the Investor Relations section of Celyad’s website at www.celyad.com/en/investors, where it will be archived for approximately 90 days.
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.
For more information about Celyad, please visit: www.celyad.com
For more information, please contact:
| For Europe: Consilium Strategic Communications Chris Gardner and Chris Welsh - T: +44 (0)20 3709 5700 – [email protected] |
| For France: NewCap Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 - [email protected] |
| For Belgium: Comfi Gunther De Backer and Sabine Leclercq - T.: +32 (0)2 290 90 90 – [email protected] |
| For the U.S.: Stern Investor Relations Will O’Connor and Michael Schaffzin – T.: +1 212.362.1200 – [email protected] |
To subscribe to Celyad’s newsletter, visit www.celyad.com
Follow us on LinkedIn & Twitter @CelyadSA
